Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;46(7):1727-1737.
doi: 10.1038/s41440-023-01272-4. Epub 2023 Apr 12.

Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension

Affiliations
Review

Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension

Michiaki Nagai et al. Hypertens Res. 2023 Jul.

Erratum in

Abstract

Heart failure (HF) in the elderly is an increasingly large and complex problem in modern society. Notably, the cause of HF with preserved ejection fraction (HFpEF) is multifactorial and its pathophysiology is not fully understood. Among these, hypertension has emerged as a pivotal factor in the pathophysiology and therapeutic targets of HFpEF. Neuronal elements distributed throughout the cardiac autonomic nervous system, from the level of the central autonomic network including the insular cortex to the intrinsic cardiac nervous system, regulate the human cardiovascular system. Specifically, increased sympathetic nervous system activity due to sympatho-vagal imbalance is suggested to be associated the relationship between hypertension and HFpEF. While several new pharmacological therapies, such as sodium-glucose cotransporter 2 inhibitors, have been shown to be effective in HFpEF, neuromodulatory therapies of renal denervation and vagus nerve stimulation (VNS) have received recent attention. The current review explores the pathophysiology of the brain-heart axis that underlies the relationship between hypertension and HFpEF and the rationale for therapeutic neuromodulation of HFpEF by non-invasive transcutaneous VNS.

Keywords: Device therapy; HFpEF; Renal denervation; Treatment-resistant hypertension; Vagus nerve stimulation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nagai M, Förster CY, Dote K, Shimokawa H. Sex hormones in heart failure revisited? Eur J Heart Fail. 2019;21:308–10. - PubMed - DOI
    1. Takami T, Hoshide S, Kario K. Differential impact of antihypertensive drugs on cardiovascular remodeling: a review of findings and perspectives for HFpEF prevention. Hypertens Res. 2022;45:53–60. - PubMed - DOI
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61. - PubMed - DOI
    1. Jin CN, Liu M, Sun JP, Fang F, Wen YN, Yu CM, et al. The prevalence and prognosis of resistant hypertension in patients with heart failure. PLoS One. 2014;9:e114958. - PubMed - PMC - DOI
    1. Seravalle G, Grassi G. Sympathetic nervous system and hypertension: new evidences. Auton Neurosci. 2022;238:102954. - PubMed - DOI